Screener
Iovance Biotherapeutics, Inc. IOVA Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | $99,313 | $59,952 | $170,743 | $109,276 |
| Total revenue | 99,313 | 59,952 | 170,743 | 109,276 |
| Costs and expenses * | ||||
| Cost of sales ** | $43,595 | $48,881 | $86,093 | $91,595 |
| Research and development ** | 58,851 | 77,928 | 121,338 | 153,895 |
| Selling, general, and administrative ** | 39,272 | 37,567 | 78,221 | 81,366 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Total costs and expenses | $151,218 | $173,726 | $303,691 | $344,271 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s total cost of revenue?
- Iovance Biotherapeutics, Inc. (IOVA) reported total cost of revenue of $43.6M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total cost of revenue changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total cost of revenue decreased by 10.8% year-over-year, from $48.88M to $43.6M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Iovance Biotherapeutics, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude